Recent articles
What Investors Need to Watch When Albemarle Reports Q1 Earnings
All three of the company's business segments are under pressure during the coronavirus pandemic.
Catalent Expects to Finish Fiscal 2020 Strong Amid Coronavirus Pandemic
It helps that the current fiscal year concludes at the end of June, but the business also remains an essential partner for the pharmaceutical industry.
WestRock Cuts Dividend to Protect Balance Sheet During Pandemic
The paper engineering leader announced a range of steps to preserve its financial position and prioritize debt reduction.
Will Clinical Trial Delays Derail Repligen's Growth?
The bioprocess leader relies on clinical trials for a significant portion of revenue. How disruptive will the coronavirus be?
The Coronavirus Pandemic Will Test Invitae's Telemedicine Ambitions
Invitae wants to provide medical-grade genetic testing to the masses. Is the business ready for the first big test?
Here's Why Athersys Tumbled 23.3% in April
The stem cell stock has delivered a 100% gain since the beginning of the year. Can it hold?
1 Question to Ask Yourself Before Buying Renewable Energy Group
Petroleum markets are in disarray, but the renewable fuels stock has lost comparatively little ground. What's going on?
Here's Why BioNTech Lost 18.7% in April
Shares simply cooled off from an impressive run-up through March, but investors are still closely watching this biotech stock.
Here's Why NeoGenomics Is Tumbling Today
The company decided to pull the trigger on a combined offering of stock and debt to pad its balance sheet during uncertain times.
Will Tandem Diabetes Care Experience a COVID-19 Slowdown?
Investors might consider the company's products to be essential, but the business could face temporary problems getting products into the hands of new customers.
Is Fate Therapeutics a Buy?
The cell therapy pioneer has a promising early-stage pipeline and just landed a huge partner. What should investors make of this high-risk, high-reward stock?
NeoGenomics Prioritizes the Public Good During COVID-19 Slowdown
Despite experiencing a double-digit decline in test volumes, the cancer genetics lab hasn't furloughed employees. It has even retooled labs to process COVID-19 swab and blood tests.
Blueprint Medicines Tumbles 20.8% on Phase 3 Study Failure
A closely watched drug candidate didn't meet the primary endpoint of a late-stage trial, which creates a wide-open opportunity for a competitor.
Are Stem Cells the COVID-19 Treatment We've All Been Waiting For?
Promising results from a very small study caused shares of stem cell stocks to soar, but investors shouldn't get too carried away just yet.
Shares of Mesoblast Tumbled Over 20% Today After Doubling Last Week
The Australian stem-cell therapy developer presented promising data for COVID-19 patients days ago, but investors took some gains off the table today.
Here's Why Invitae Stock Popped as Much as 13.2% Today
A rising tide lifts all ships.
The Most Important Thing to Watch When NeoGenomics Reports Earnings
Test volumes fell by double digits at the end of March compared with the year-ago period. How long does management think that trend will continue?
Here's Why Pluristem Therapeutics Jumped Over 28% Today
The stem cell developer found a financing solution that won't dilute shareholders. Well, not immediately, anyway.
Mesoblast Soars 219% on Promising COVID-19 Clinical Trial Data
The small-scale study, including just 12 patients, could signal big potential for the stem cell company's drug candidate.
2 Top Growth Stocks to Buy Right Now
These two stocks should be relatively insulated from the economic downturn just over the horizon.